HepaFatSmart -

GUDID 09355529000095

Standalone software as medical device (SaMD) designed to automatically analyse within seconds magnetic resonance imaging (MRI) datasets to generate an estimate of the patient’s volumetric liver fat fraction (VLFF), converted into proton density fat fraction (PDFF) and steatosis grade. No user input is required for the analysis thus minimising the impact of human error on obtained results. HepaFatSmart is intended for the quantitative evaluation of volumetric liver fat fraction (VLFF), proton density fat fraction (PDFF) and liver steatosis grading. It utilises magnetic resonance images that exploit the difference in resonance frequencies between hydrogen nuclei in water and triglyceride fat. The quantitative triglyceride fat fraction is based on the measurement of a magnetic resonance parameter that reflects the ratio of the proton density signal of triglyceride fat to the total proton density signal in the liver. When interpreted by a trained physician, the results provide information that can aid in diagnosis. HepaFatSmart is indicated to: • Support clinical diagnoses in individuals with confirmed or suspected fatty liver disease; • Assessment of liver fat content to support the subsequent clinical decision-making processes for patients under management of diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), viral hepatitis. • Support the subsequent clinical decision-making processes for patients Results, when interpreted by a trained physician can be used to support clinical diagnoses about the status of liver fat content, the subsequent clinical decision-making processes for the management of fatty liver related diseases.

RESONANCE HEALTH ANALYSIS SERVICES PTY LTD

MRI system application software
Primary Device ID09355529000095
NIH Device Record Keyc3f1989b-34cd-4c23-8dbd-25122c0f6c0b
Commercial Distribution StatusIn Commercial Distribution
Brand NameHepaFatSmart
Version Model Numberv2.0.0
Catalog Number-
Company DUNS740449913
Company NameRESONANCE HEALTH ANALYSIS SERVICES PTY LTD
Device Count1
DM Exemptfalse
Pre-market Exemptfalse
MRI Safety StatusLabeling does not contain MRI Safety Information
Human Cell/Tissue Productfalse
Device Kitfalse
Device Combination Productfalse
Single Usefalse
Lot Batchfalse
Serial Numberfalse
Manufacturing Datefalse
Expiration Datefalse
Donation Id Numberfalse
Contains Natural Rubber Latexfalse
Labeled No Natural Rubber Latexfalse
RX Perscriptiontrue
OTC Over-The-Counterfalse

Customer Support Contacts

Phone+61892865300
Emailquality@resonancehealth.com
Phone+61892865300
Emailquality@resonancehealth.com
Phone+61892865300
Emailquality@resonancehealth.com
Phone+61892865300
Emailquality@resonancehealth.com
Phone+61892865300
Emailquality@resonancehealth.com
Phone+61892865300
Emailquality@resonancehealth.com
Phone+61892865300
Emailquality@resonancehealth.com
Phone+61892865300
Emailquality@resonancehealth.com
Phone+61892865300
Emailquality@resonancehealth.com
Phone+61892865300
Emailquality@resonancehealth.com
Phone+61892865300
Emailquality@resonancehealth.com

Device Identifiers

Device Issuing AgencyDevice ID
GS109355529000095 [Primary]

FDA Pre-market Approvals/Notifications & deNovo

FDA Product Code

LNHSystem, Nuclear Magnetic Resonance Imaging

Sterilization

Steralize Prior To Usefalse
Device Is Sterilefalse

Device Entry Metadata

Public Version StatusNew
Device Record StatusPublished
Public Version Number1
Public Version Date2024-05-07
Device Publish Date2024-04-29

Devices Manufactured by RESONANCE HEALTH ANALYSIS SERVICES PTY LTD

09369998038619 - FerriSmart2024-06-17 FerriSmart is a stand-alone software application that automatically analyses multi slice, spin echo MRI data sets encompassing t
09355529000057 - FerriSmart2024-06-14 FerriSmart is a standalone software as a medical device indicated for the evaluation of liver R2 and liver iron concentration (L
09355529000095 - HepaFatSmart2024-05-07Standalone software as medical device (SaMD) designed to automatically analyse within seconds magnetic resonance imaging (MRI) datasets to generate an estimate of the patient’s volumetric liver fat fraction (VLFF), converted into proton density fat fraction (PDFF) and steatosis grade. No user input is required for the analysis thus minimising the impact of human error on obtained results. HepaFatSmart is intended for the quantitative evaluation of volumetric liver fat fraction (VLFF), proton density fat fraction (PDFF) and liver steatosis grading. It utilises magnetic resonance images that exploit the difference in resonance frequencies between hydrogen nuclei in water and triglyceride fat. The quantitative triglyceride fat fraction is based on the measurement of a magnetic resonance parameter that reflects the ratio of the proton density signal of triglyceride fat to the total proton density signal in the liver. When interpreted by a trained physician, the results provide information that can aid in diagnosis. HepaFatSmart is indicated to: • Support clinical diagnoses in individuals with confirmed or suspected fatty liver disease; • Assessment of liver fat content to support the subsequent clinical decision-making processes for patients under management of diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), viral hepatitis. • Support the subsequent clinical decision-making processes for patients Results, when interpreted by a trained physician can be used to support clinical diagnoses about the status of liver fat content, the subsequent clinical decision-making processes for the management of fatty liver related diseases.
09355529000095 - HepaFatSmart2024-05-07 Standalone software as medical device (SaMD) designed to automatically analyse within seconds magnetic resonance imaging (MRI) d
09355529000033 - T1CMR Phantom (1.5T)2024-04-25 The T1CMR Phantom contains a range of nickel chloride in agarose solutions that mimic cardiac T1 and T2 values. T1 measurement i
09355529000064 - T1CMR Phantom (3.0T)2024-04-25 The T1CMR Phantom contains a range of nickel chloride in agarose solutions that mimic cardiac T1 and T2 values. T1 measurement i
09355529000071 - T2CMR Phantom2024-04-25 Cardiovascular magnetic resonance (CMR) T2 mapping is key to quantifying myocardial inflammation. The T2CMR Phantom is made of n
09355529000088 - R2*/T2* Phantom2024-04-25 The R2*/T2* phantom is a medical device accessory intended to be used as an alternative to human test subject to avoid potential
09355529000026 - FerriScan Phantom2024-04-18 Sealed pack containing 15 vials of varying concentrations (0 mM to 3.2 mM) of aqueous manganese chloride solutions in 10 mM hydr

Trademark Results [HepaFatSmart]

Mark Image

Registration | Serial
Company
Trademark
Application Date
HEPAFATSMART
HEPAFATSMART
79379758 not registered Live/Pending
Resonance Health Analysis Services Pty Ltd
2023-08-17

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.